# Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

> **NCT04656652** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 605 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** DS-1062a
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04656652
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-21
- **Primary completion:** 2024-05-10
- **Final completion:** 2027-02-15
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656652, "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04656652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*